Health-related Quality of Life After Stereotactic Radiosurgery in Patients with Brain Metastases

Overview

Journal Support Care Cancer

Specialties Critical Care
Oncology

Date 2023 Nov 26

PMID 38008876

Authors

Elaine A C Albers

Kelly M de Ligt

Lonneke V van de Poll-Franse

Annette Compter

Michiel B de Ruiter

Sanne B Schagen

Affiliations

Soon will be listed here.

Abstract

Purpose: This study aimed to assess health-related quality of life (HRQoL) in patients with brain metastases treated with stereotactic radiosurgery (SRS) and to identify factors associated with this.

Methods: HRQoL was measured pre-SRS, at 3- and 6-month follow-up. Physical functioning, cognitive functioning, role functioning, and fatigue were analyzed with the EORTC QLQ-C30 questionnaire. Motor dysfunction, future uncertainty, visual disorder, communication deficit, and headaches were analyzed with the EORTC QLQ-BN20. Clinically important symptom or functional impairment was assessed following set thresholds. Factors associated with impairment were identified through multivariable logistic regression analyses.

Results: At baseline, 178 patients were included; 54% (n=96) completed questionnaires at 3 months and 39% (n=70) at 6 months. Before SRS, 29% of linear accelerator (LINAC) patients reported physical and cognitive impairment, while 25% reported impairment for fatigue. At 6 months, 39%, 43%, and 57% of LINAC patients reported impairment respectively. Forty-five percent of Gamma Knife (GK) patients reported impairment pre-SRS for physical, cognitive functioning, and fatigue. At 6 months, 48%, 43%, and 33% of GK patients reported impairment respectively. Except for role functioning, pre-SRS symptom and functioning scores were associated with impairment at 3 months, whereas scores at 3 months were associated with impairment at 6 months. Age, gender, systemic therapy, and intracranial progression were not associated with clinically important impairment.

Conclusion: As 33-57% of patients with brain metastases reported symptom burden and functional impairments that were of clinical importance, it is recommended to pay attention to the HRQoL outcomes of these patients during clinical encounters.

References

Hatiboglu M, Akdur K, Sawaya R . Neurosurgical management of patients with brain metastasis. Neurosurg Rev. 2018; 43(2):483-495. DOI: 10.1007/s10143-018-1013-6. View

Fox B, Cheung V, Patel A, Suki D, Rao G . Epidemiology of metastatic brain tumors. Neurosurg Clin N Am. 2010; 22(1):1-6, v. DOI: 10.1016/j.nec.2010.08.007. View

Dhakal S, Peterson 3rd C, Milano M . Radiation therapy in the management of patients with limited brain metastases. Am J Clin Oncol. 2012; 37(2):208-14. DOI: 10.1097/COC.0b013e3182546807. View

Rastogi K, Bhaskar S, Gupta S, Jain S, Singh D, Kumar P . Palliation of Brain Metastases: Analysis of Prognostic Factors Affecting Overall Survival. Indian J Palliat Care. 2018; 24(3):308-312. PMC: 6069611. DOI: 10.4103/IJPC.IJPC_1_18. View

Soffietti R, Kocher M, Abacioglu U, Villa S, Fauchon F, Baumert B . A European Organisation for Research and Treatment of Cancer phase III trial of adjuvant whole-brain radiotherapy versus observation in patients with one to three brain metastases from solid tumors after surgical resection or radiosurgery:.... J Clin Oncol. 2012; 31(1):65-72. DOI: 10.1200/JCO.2011.41.0639. View

Miller J, Kotecha R, Barnett G, Suh J, Angelov L, Murphy E . Quality of Life following Stereotactic Radiosurgery for Single and Multiple Brain Metastases. Neurosurgery. 2017; 81(1):147-155. DOI: 10.1093/neuros/nyw166. View

Wong E, Zhang L, Rowbottom L, Chiu N, Chiu L, McDonald R . Symptoms and quality of life in patients with brain metastases receiving whole-brain radiation therapy. Support Care Cancer. 2016; 24(11):4747-59. DOI: 10.1007/s00520-016-3326-8. View

Verhaak E, Gehring K, Hanssens P, Aaronson N, Sitskoorn M . Health-related quality of life in adult patients with brain metastases after stereotactic radiosurgery: a systematic, narrative review. Support Care Cancer. 2019; 28(2):473-484. PMC: 6954134. DOI: 10.1007/s00520-019-05136-x. View

Bezjak A, Adam J, Barton R, Panzarella T, Laperriere N, Wong C . Symptom response after palliative radiotherapy for patients with brain metastases. Eur J Cancer. 2002; 38(4):487-96. DOI: 10.1016/s0959-8049(01)00150-2. View

10.

Reddy N, Brown F, Fogarasi M, Yu J, Hess J, Chiang V . Long-term Quality of Life in Survivors of Brain Metastases: A Roller Coaster of Perspective. Cureus. 2018; 10(3):e2358. PMC: 5963947. DOI: 10.7759/cureus.2358. View

11.

Kepka L, Tyc-Szczepaniak D, Osowiecka K, Sprawka A, Trabska-Kluch B, Czeremszynska B . Quality of life after whole brain radiotherapy compared with radiosurgery of the tumor bed: results from a randomized trial. Clin Transl Oncol. 2017; 20(2):150-159. DOI: 10.1007/s12094-017-1703-5. View

12.

Aoyama H, Shirato H, Tago M, Nakagawa K, Toyoda T, Hatano K . Stereotactic radiosurgery plus whole-brain radiation therapy vs stereotactic radiosurgery alone for treatment of brain metastases: a randomized controlled trial. JAMA. 2006; 295(21):2483-91. DOI: 10.1001/jama.295.21.2483. View

13.

Ferini G, Viola A, Valenti V, Tripoli A, Molino L, Marchese V . Whole Brain Irradiation or Stereotactic RadioSurgery for five or more brain metastases (WHOBI-STER): A prospective comparative study of neurocognitive outcomes, level of autonomy in daily activities and quality of life. Clin Transl Radiat Oncol. 2021; 32:52-58. PMC: 8649107. DOI: 10.1016/j.ctro.2021.11.008. View

14.

Verhaak E, Gehring K, Hanssens P, Sitskoorn M . Health-related quality of life of patients with brain metastases selected for stereotactic radiosurgery. J Neurooncol. 2019; 143(3):537-546. PMC: 6591192. DOI: 10.1007/s11060-019-03186-z. View

15.

Habets E, Dirven L, Wiggenraad R, Verbeek-de Kanter A, Lycklama A Nijeholt G, Zwinkels H . Neurocognitive functioning and health-related quality of life in patients treated with stereotactic radiotherapy for brain metastases: a prospective study. Neuro Oncol. 2015; 18(3):435-44. PMC: 4767242. DOI: 10.1093/neuonc/nov186. View

16.

Harikar M, Venkataram T, Palmisciano P, Scalia G, Baldoncini M, Cardali S . Comparison of Staged Stereotactic Radiosurgery and Fractionated Stereotactic Radiotherapy in Patients with Brain Metastases > 2 cm without Prior Whole Brain Radiotherapy: A Systematic Review and Meta-Analysis. World Neurosurg. 2023; 178:213-232.e6. DOI: 10.1016/j.wneu.2023.07.143. View

17.

Aaronson N, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez N . The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst. 1993; 85(5):365-76. DOI: 10.1093/jnci/85.5.365. View

18.

Osoba D, Aaronson N, Muller M, Sneeuw K, Hsu M, Yung W . The development and psychometric validation of a brain cancer quality-of-life questionnaire for use in combination with general cancer-specific questionnaires. Qual Life Res. 1996; 5(1):139-50. DOI: 10.1007/BF00435979. View

19.

Rahimy E, Dudley S, von Eyben R, Pollom E, Seiger K, Modlin L . Phase I/II Dose-Escalation Trial of 3-Fraction Stereotactic Radiosurgery for Resection Cavities From Large Brain Metastases: Health-related Quality of Life Outcomes. Am J Clin Oncol. 2021; 44(11):588-595. DOI: 10.1097/COC.0000000000000868. View

20.

Sebastian N, Glenn C, Hughes R, Raval R, Chu J, DiCostanzo D . Linear accelerator-based radiosurgery is associated with lower incidence of radionecrosis compared with gamma knife for treatment of multiple brain metastases. Radiother Oncol. 2020; 147:136-143. DOI: 10.1016/j.radonc.2020.03.024. View